Med-tech Enovis beats Q3 sales estimates, hikes FY outlook

Reuters11-06
Med-tech Enovis beats Q3 sales estimates, hikes FY outlook

Overview

  • Enovis Q3 sales grow 9%, beating analyst expectations

  • Adjusted EPS for Q3 beats consensus

  • Company raises full-year 2025 adjusted EBITDA and EPS guidance

Outlook

  • Enovis expects 2025 revenue between $2.24 bln and $2.27 bln

  • Revenue guidance adjusted due to $15 mln reduction from Dr. Comfort divestitur

  • Company raises full-year 2025 adjusted EBITDA guidance to $395-405 mln

  • Enovis increases full-year 2025 adjusted EPS guidance to $3.10-3.25

Result Drivers

  • RECONSTRUCTIVE SALES - Reconstructive sales grew 12% year-over-year, driven by stable markets and new product momentum

  • GOODWILL IMPAIRMENT - Net loss impacted by a $548 mln non-cash goodwill impairment charge in Recon and P&R units

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$548.91 mln

$538.50 mln (11 Analysts)

Q3 Adjusted EPS

Beat

$0.75

$0.65 (11 Analysts)

Q3 Gross Margin

59.90%

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Enovis Corp is $52.50, about 40% above its November 5 closing price of $31.49

Press Release: ID:nGNX6x2q7w

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment